Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eli Lilly and Co (LLY) Gets Dedicated Humulin R U-500 Insulin Syringe From Becton Dickinson

Becton Dickinson (BD) has recently unveiled BD U-500 Insulin Syringe, a syringe dedicated to the Humulin R U-500 insulin of Eli Lilly and Co (NYSE:LLY).

BD U-500 Insulin Syringe

The BD U-500 Insulin Syringe is specifically designed to administer the Humulin R U-500 insulin among patients properly.

The Humulin R U-500 insulin is prescribed to patients who need a higher dose of insulin on a daily basis. It has five-times the insulin compared to common insulin, meeting the needs of patients whose bodies are insulin resistant.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, internet, male, drugstore, service,

wavebreakmedia/Shutterstock.com

Prior to the the BS U-500 Insulin Syringe, they had to settle and risk using traditional syringes since the launch of the Humulin R U-500 insulin in 1994. Patients and healthcare providers had to calculate dose conversations thoroughly in order to administer the correct dosage using traditional syringes. Administering the incorrect dosage can potentially lead to fatalities.

“At Lilly, we recognize that people with diabetes have diverse needs and that their insulin delivery devices should reflect their individual needs, and we’re pleased to partner with BD to provide a dedicated U-500 insulin syringe,” emphasized Jeffrey Jackson, Ph.D., a US Medical Affairs Medical Fellow at Lilly Diabetes.

Presentation of New Data from Clinical Development Programs

In other news, Eli Lilly and Co (NYSE:LLY) will present at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting, which will begin on Friday. The company will present new safety and efficacy data from Phase III clinical trials evaluating baricitinib and other new data from other clinical development programs seeking to treat rheumatoid arthritis (RA). The company will also present six abstracts and an oral presentation featuring results from the Phase III clinical trial evaluating Taltz (ixekizumab) for the treatment of patients with moderate-to-severe active psoriatic arthritis and plaque psoriasis.

Eli Lilly and Co (NYSE:LLY) believes that its efforts will not just expand its portfolio but will most importantly improve patient care.

On Wednesday, Eli Lilly surged by 5.90% to $78.39.

Follow Lilly Eli & Co (NYSE:LLY)
Trade (NYSE:LLY) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.

Loading Comments...